Pharmaceuticals India

India Radiopharmaceuticals Market Analysis, 2024–2034

India Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $148.4 Mn Estimated value
Estimate 2025 $167.4 Mn 1.8% of the global market
Projected 2034 $495.1 Mn 195.7% Adds $327.6 Mn over 9 forecast years
CAGR 2025–2034 12.8% Faster than 60% of 180 Pharmaceuticals markets here
Key players 6 +1
  • India is 1.85% of the global market.
  • In APAC, the largest is China at $813.1 Mn.
  • Fastest growing: India (this report) at 12.8% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$327.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Radiopharmaceuticals Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $148.4 Mn — —
2025 (base) $167.4 Mn +$19.0 Mn —
2026 (forecast) $188.9 Mn +$21.4 Mn +12.8%
2027 (forecast) $213.1 Mn +$24.2 Mn +27.2%
2028 (forecast) $240.3 Mn +$27.3 Mn +43.5%
2029 (forecast) $271.1 Mn +$30.8 Mn +61.9%
2030 (forecast) $305.8 Mn +$34.7 Mn +82.6%
2031 (forecast) $344.9 Mn +$39.1 Mn +106%
2032 (forecast) $389.1 Mn +$44.2 Mn +132.4%
2033 (forecast) $438.9 Mn +$49.8 Mn +162.1%
2034 (forecast) $495.1 Mn +$56.2 Mn +195.7%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $9.08 Bn
  2. North America $4.23 Bn
  3. US $3.20 Bn
  4. APAC $1.89 Bn
  5. Europe $1.61 Bn
  6. Canada $810.3 Mn
  7. China $813.1 Mn
  8. Japan $623.3 Mn
  9. Middle East $380.3 Mn
  10. Latin America $363.4 Mn
  11. Germany $319.4 Mn
  12. France $271.0 Mn
  13. Brazil $259.9 Mn
  14. UK $242.1 Mn
  15. Italy $217.7 Mn
  16. Ecuador $206.3 Mn
  17. Spain $197.1 Mn
  18. India (this report) $167.4 Mn
  19. Africa $159.7 Mn
  20. Mexico $153.7 Mn
  21. Saudi Arabia $134.9 Mn
  22. Australia $111.2 Mn
  23. Russia $87.0 Mn
  24. New Zealand $86.7 Mn
  25. South Africa $65.3 Mn
  26. UAE $39.7 Mn
  27. Egypt $29.7 Mn
  28. Philippines $19.8 Mn
  29. Malaysia $16.2 Mn
  30. Hong Kong $14.3 Mn
  31. Singapore $10.9 Mn
  32. Thailand $9.8 Mn
  33. Kenya $6.7 Mn

The India Radiopharmaceuticals Market Analysis Executive Summary

Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.

Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).

India Radiopharmaceuticals Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.

Competitive Landscape for Radiopharmaceuticals Market in India

The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in India

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.

Clinical trials

1 active trial in India

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Novartis AG 19 active trials on ClinicalTrials.gov (opens in a new tab)
  2. AstraZeneca 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Eli Lilly and Company 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Fusion Pharmaceuticals Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. AC Immune (Switzerland) 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 2,809 papers since 2021 (worldwide)

  1. Evaluation and an Exploratory Human Study of 99mTc-Labeled PSMA-Targeting Agents with Reduced Renal Uptake via Proline Incorporation. Journal of medicinal chemistry, 2026
  2. Synthesis and Preclinical Evaluation of Novel (203)Pb-PSMA Radioligands as Leads for the Development of (203/212)Pb-PSMA Theranostics. Molecular imaging and biology, 2026
  3. Radiopharmaceuticals in Molecular Neuroimaging: Radiotracers in Development. Neuroimaging clinics of North America, 2026
  4. Radiopharmaceuticals in Molecular Neuroimaging: Food and Drug Administration-Approved Radiotracers. Neuroimaging clinics of North America, 2026
  5. Nitroimidazole containing cyclicpeptide [(68)Ga]Ga-ZJUIQB-G002 as a new FAP-targeting radionuclide tracer. European journal of medicinal chemistry, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Radiopharmaceuticals in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Radiopharmaceuticals are running in India?
1 study is recruiting, active or about to start in India.[4]
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Radiopharmaceuticals in India? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in India

See all
Same topic, other categories

Related on oncology

See the topic